PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-75.16%
Both yoy net incomes decline, with CRK at -102.85%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-0.31%
Both reduce yoy D&A, with CRK at -100.00%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-724.32%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
-62.99%
Both reduce yoy usage, with CRK at -254.73%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.99%
Both reduce yoy usage, with CRK at -7111.49%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
101.96%
Lower 'other non-cash' growth vs. CRK's 10762.39%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
6.77%
Some CFO growth while CRK is negative at -28.37%. John Neff would note a short-term liquidity lead over the competitor.
31.44%
CapEx growth well above CRK's 23.79%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-112.12%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
80.28%
Purchases growth of 80.28% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-31.44%
We reduce yoy sales while CRK is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
24.06%
Growth of 24.06% while CRK is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
26.90%
Investing outflow well above CRK's 23.79%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
850.00%
Stock issuance far above CRK's 511.27%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.